MedTrace Logo

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

NCT02605525 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-02-07

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)

Conditions

  • Immunoglobulin A Nephropathy

Interventions

BIOLOGICAL

SM101

Human soluble recombinant Fcγ Receptor IIB

OTHER

Placebo

L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-11-30
Completion
2016-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605525 on ClinicalTrials.gov